SUMMARY: Adverse effects possibly due to the active clotting factors are sometimes reported upon administration of some preparations of Factor IX complex having conformed to the specifications in the Japanese Minimum Requirements for Biological Products. The author, therefore, proposed the revision of the test method for the absence of active clotting factors in the Minimum Requirements by introducing calcium ion into the test medium.
INTRODUCTION
. Sas et al. (1975) , nonactivated partial thromboplastin time by Kingdon et al. (1975) , tests using chromogenic substrate (S-2222), Factor VIII Inhibition-Bypassing Activity (FEIBA) test, (Briet and Veltkamp, 1978) etc.
In this report, proposed will be a test method by which all the active clotting factors possibly present in preparations of Factor IX complex can be detected by simply modifying the test medium of the current method.
The outline of the report was presented by the author to the Congress of the Japanese Society of Clinical Pathology (1975 and 1976) 2) The author's modification of (1): 0.025 M calcium chloride solution was added to the reaction mixture of (1).
3) .5.9) was followed and the activity was expressed in terms of a relative value to normal human plasma.
RESULTS
All the samples were found to conform to the specification in the Minimum Requirements (1973) when tested by the method described therein. However, it was found that when the reconstituted test samples were stored in a frozen state (below -20 C) and tested again in the same method, six out of 19 products were found to clot within few minutes. Thus, the samples once stored in a frozen state were excluded from the subsequent experiments. Table I , about half of the 14 products clotted within an hour when they were tested by the modified method, that is, in the presence of calcium ion. Five (Nos. 1, 7, 8, 10 and 11) out of the six samples which gave clotting time of less than 10 min in the modified method also showed TGt5o of less than 30 min.
Furthermore, the potencies of the seven samples (Nos. 2, 3, 4, 5, 6, 12 and 13) with better results in the modified test method were within a range of 19.0-48.6 times normal human plasma (mean: 27.9), while those with poorer results (Nos. 1, 7, 8, 9, 10, 11 and 14) showed potencies of 15.0-27.2 (mean: 21.3) times normal plasma. Thus, the products giving shorter clotting time in the modified test for active clotting factors did not show higher potencies than those of the products in which no or little active clotting factor was demonstrated.
Addition of absorbed bovine serum for supplying Factor V (column 2 of Table I ) did not shorten the clotting time of the samples showing fairly good results in the author's modified method. It is, therefore, unlikely that the clotting factor in these products were activated not leading to the step of prothrombin activation because the amount of Factor V available in the test medium was too little.
As seen in Table II , addition of heparin alone 0.65 U/ml and 3.25 U/ml to the reaction mixture did not appreciably improve the results with the test samples in which the active clotting factors were detected by the author's modified method. The amount of the added heparin was lower than the one (4.5 U/ml) used as anticoagulant for Whole Blood (Human) in the United States, but was enough to lengthen the clotting time of normal plasma from 8.5 min to longer than 2 hr. Thus, the active clotting factor(s) or the mechanism of coagulation process in these test materials seems unaffected by heparin, at least in the absence of its cofactor.
Thirteen samples were tested for the Xa contents with chromogenic substrate. The contents ranged between 0.5% and 1.4% of the normal human plasma activated by Russell Viper Venom and calcium chloride. 
